Study of Human Primary Cancer Tissue Implanted in Mice Lacking Bv8/PH-2 in Their Bone Marrow-derived Cells
N/A
18 Years
85 Years
18 Years
85 Years
Not Enrolling
Both
Cancer
Both
Cancer
Trial Information
Study of Human Primary Cancer Tissue Implanted in Mice Lacking Bv8/PH-2 in Their Bone Marrow-derived Cells
1-10 grams of human cancer tissue will be taken from surgical specimen without interference
to the pathological data gathering process. those tissues will be implanted in nude mice
that will either be treated with anti-Bv8 antibodies or will be transplanted with bone
marrow in which Bv8 expression is silenced.
Inclusion Criteria:
- ages 18-85 years
- Pathologically-confirmed diagnosis of pancreatic ductal adenocarcinoma undergoing
surgical pancreaticoduodenectomy
Exclusion Criteria:
- refuse to take part
- preoperative chemotherapy
Type of Study:
Observational
Study Design:
N/A
Principal Investigator
Erez Hasnis, MD;PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Rambam Health Care Campus
Authority:
Israel: Ministry of Health
Study ID:
Bv8/PK-2CTIL
NCT ID:
NCT01656824
Start Date:
August 2012
Completion Date:
September 2013
Related Keywords:
- Cancer
- Bv8/PK-2
- MDSC Myeloid Derived Suppressor Cells
- BMDC Bone Marrow Derived Cells
- Angiogenesis
- Pancreatic Cancer
Name | Location |
|---|
